Table 1.
Overall and stratified analyses of serological response in pwMS with DMTs after COVID-19 vaccination.
| DMT | Dosage | No. of datasets | OR (95% CI) | P(Z) | P(Q) | I2 |
|---|---|---|---|---|---|---|
| Anti-CD20 | Partial | 5 | 0.029 (0.015-0.057) | <10−5 | 0.478 | 0% |
| Full | 23 | 0.019 (0.013-0.030) | <10−5 | 0.953 | 0% | |
| Overall | 28 | 0.022 (0.015-0.031) | <10−5 | 0.936 | 0% | |
| S1PRMs | Partial | 3 | 0.046 (0.018-0.115) | <10−5 | 0.319 | 12.6% |
| Full | 17 | 0.027 (0.013-0.059) | <10−5 | 0.035 | 42.0% | |
| Overall | 20 | 0.029 (0.015-0.056) | <10−5 | 0.031 | 40.6% | |
| IFN-β | Partial | 3 | 1.762 (0.293-10.581) | 0.536 | 0.999 | 0% |
| Full | 4 | 1.226 (0.444-3.389) | 0.694 | 0.480 | 0% | |
| Overall | 7 | 1.339 (0.553-3.243) | 0.517 | 0.858 | 0% | |
| GA | Partial | 3 | 1.518 (0.249-9.259) | 0.651 | 0.981 | 0% |
| Full | 3 | 1.145 (0.372-3.524) | 0.814 | 0.693 | 0% | |
| Overall | 6 | 1.238 (0.477-3.218) | 0.661 | 0.974 | 0% | |
| DMF | Partial | 3 | 0.731 (0.162-3.293) | 0.683 | 0.195 | 38.9% |
| Full | 2 | 1.883 (0.467-7.595) | 0.374 | 0.180 | 44.4% | |
| Overall | 5 | 1.157 (0.382-3.507) | 0.796 | 0.078 | 52.4% | |
| TERI | Partial | 2 | 0.424 (0.067-2.677) | 0.362 | 0.663 | 0.0% |
| Full | 2 | 0.484 (0.068-3.424) | 0.467 | 0.192 | 41.2% | |
| Overall | 4 | 0.570 (0.207-1.568) | 0.276 | 0.579 | 0.0% | |
| NTZ | Partial | 3 | 0.629 (0.269-1.470) | 0.284 | 0.756 | 0.0% |
| Full | 4 | 0.803 (0.361-1.787) | 0.591 | 0.401 | 0.0% | |
| Overall | 7 | 0.716 (0.400-1.281) | 0.260 | 0.722 | 0.0% | |
| CLAD | Overall | 4 | 0.391 (0.151-1.011) | 0.053 | 0.956 | 0.0% |
| ALE | Partial | 1 | 0.239 (0.022-2.606) | 0.240 | NA | NA |
| Full | 3 | 0.475 (0.046-4.913) | 0.533 | 0.118 | 53.2% | |
| Overall | 4 | 0.401 (0.079-2.052) | 0.273 | 0.210 | 33.7% |
NA: not available, OR: odds ratio, CI: 95% confidence interval.